SCHEMBL15926416

SCHEMBL15926416

Cc1cc(N(C)C)cc2c1Nc1c(C)cc(N3CCOCC3)cc1S2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
MAPT P10636 13/20 0.39
MEN1 O00255 9/20 0.39
KMT2A Q03164 9/20 0.39
RAB9A P51151 8/20 0.39
NPC1 O15118 7/20 0.39
SMN1; SMN2 Q16637 6/20 0.39
PKM P14618 1/20 0.39
ALDH1A1 P00352 9/20 0.36
HTT P42858 3/20 0.36
USP2 O75604 1/20 0.36
TP53 P04637 1/20 0.36
ALOX15 P16050 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SLC2A1 P11166 1/20 0.36
HPGD P15428 3/20 0.33
GAA P10253 2/20 0.33
NR1H4 Q96RI1 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15925819 0.89 MAPT (0.45) KDM4EMAPTMEN1KMT2ARAB9A
Iodide SCHEMBL13386230 0.89 MEN1 (0.36) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL15875837 0.86 MAP4K1 (0.33) KDM4EMAPTRAB9ANPC1SMN1; SMN2
SCHEMBL15875812 0.86 ADRB1 (0.42) KDM4EMAPTHPGDCYP1A2CYP2C19
SCHEMBL13386335 0.85 MAPT (0.43) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL17896427 0.84 MAPT (0.42) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL15925818 0.84 MAPT (0.42) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL15926417 0.84 MEN1 (0.35) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL13386392 0.83 LGMN (0.44) KDM4EMAPTMEN1KMT2ARAB9A
SCHEMBL16004720 0.83 KDM4E (0.43) KDM4EMAPTMEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease Prosetta Antiviral, Inc. 2017-06-01 US disclosed
US-9382221-B2 Compounds, compositions, and methods for treating alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2016-07-05 US disclosed
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE Prosetta Antiviral, Inc. 2014-10-23 US disclosed
US-8796448-B1 Compounds, compositions, and methods for treating Alzheimer's disease PROSETTA ANTIVIRAL INC. (US) 2014-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170151253-A1 Compounds, Compositions, and Methods for Treating Alzheimer's Disease PSEN1, APP, PSEN2 KDM4E 68/4885MAPT 11/4885MEN1 1540/4885
US-20140315897-A1 COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING ALZHEIMER'S DISEASE PSEN1, APP, PSEN2 KDM4E 68/4885MAPT 11/4885MEN1 1540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.